PureTech Health PLC (GB:PRTC)
LSE:PRTC
Want to see GB:PRTC full AI Analyst Report?
PRTC Stock Chart & Stats
134.80 p
0.20 p(0.14%)
At close: 4:00 PM EST
134.80 p
0.20 p(0.14%)
Day’s Range― - ―
52-Week Range104.71 p - 148.00 p
Previous CloseN/A
Volume88.39K
Average Volume (3M)444.90K
Market Cap
£320.83M
Enterprise Value172.93M
Total Cash (Recent Filing)£279.00M
Total Debt (Recent Filing)£19.76M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding243,418,180
10 Day Avg. Volume437,187
30 Day Avg. Volume444,904
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.30
Price to Sales (P/S)85.14
P/FCF Ratio-4.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.65
Revenue Forecast (FY)£49.50M
Bulls Say, Bears Say
Bulls Say
Hub-and-spoke Monetization ModelPublic-listing progress at Seaport and an increased stake validate PureTech’s venture‑builder model and demonstrated ability to scale and monetize founded entities. This structural capability to create sellable or investable businesses underpins repeatable, non‑dilutive value creation over the medium term.
Clinical Program Advancement (Gallop LYT‑200)Robust Phase Ib safety and dose selection for LYT‑200 materially de‑risks a lead program and enables a clear regulatory path. A registration‑enabling trial would shift program funding models and long‑term value potential, reducing binary program risk if execution follows clinical signals.
Relatively Strong Balance SheetA sizable equity cushion and low absolute debt provide financial flexibility to support multi‑year development timelines. While the cushion has shrunk from prior years, current capital resources and low leverage reduce short‑term insolvency risk and enable participation in founded‑entity financings.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow forces reliance on balance‑sheet resources or external financing for ongoing R&D and trial starts. Over multiple quarters this erodes equity headroom and increases execution risk for late‑stage programs if capital markets or monetization windows tighten.
Funding And Execution Risk For Late‑stage ProgramsMajor value inflection depends on third‑party financing execution for large Phase III/registration trials. Failure or delay in securing partner funding could force deeper internal funding, dilution, or program delays, making long‑term value generation contingent on successful capital markets or partner deals.
Very Low, Volatile Revenue And EarningsMinimal and milestone‑driven revenue means recurring cash inflows are unpredictable and insufficient to fund development. Structural reliance on irregular monetizations or milestones increases sensitivity to timing risks and reduces ability to self‑fund growth or absorb clinical setbacks over the medium term.
PureTech Health News
PRTC FAQ
What was PureTech Health PLC’s price range in the past 12 months?
PureTech Health PLC lowest share price was 104.71 p and its highest was 148.00 p in the past 12 months.
What is PureTech Health PLC’s market cap?
PureTech Health PLC’s market cap is £320.83M.
When is PureTech Health PLC’s upcoming earnings report date?
PureTech Health PLC’s upcoming earnings report date is Aug 27, 2026 which is in 99 days.
How were PureTech Health PLC’s earnings last quarter?
PureTech Health PLC released its earnings results on Apr 29, 2026. The company reported -0.202 p earnings per share for the quarter, missing the consensus estimate of -0.143 p by -0.059 p.
Is PureTech Health PLC overvalued?
According to Wall Street analysts PureTech Health PLC’s price is currently Overvalued.
Does PureTech Health PLC pay dividends?
PureTech Health PLC does not currently pay dividends.
What is PureTech Health PLC’s EPS estimate?
PureTech Health PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PureTech Health PLC have?
PureTech Health PLC has 243,418,180 shares outstanding.
What happened to PureTech Health PLC’s price movement after its last earnings report?
PureTech Health PLC reported an EPS of -0.202 p in its last earnings report, missing expectations of -0.143 p. Following the earnings report the stock price went down -4.154%.
Which hedge fund is a major shareholder of PureTech Health PLC?
Currently, no hedge funds are holding shares in GB:PRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PureTech Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.20%
12-Months-Change
Fundamentals
Return on Equity
-31.83%
Trailing 12-Months
Asset Growth
-17.38%
Trailing 12-Months
Company Description
PureTech Health PLC
PureTech Health (PRTC) is a biotechnology company focused on discovering, developing, and commercializing innovative therapies for serious diseases. The company operates primarily in the health and biotechnology sectors, leveraging its expertise in drug development to create a diverse pipeline of therapeutic candidates across various domains, including immunology, neurology, and oncology. PureTech also engages in collaborations and partnerships with other biotech and pharmaceutical companies to advance its proprietary technologies and products.
Technical Analysis
Avacta Group plc
―
ImmuPharma
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―
Options Prices
Currently, No data available
---